IAIM
FHTX icon

International Assets Investment Management’s Foghorn Therapeutics FHTX Stock Holding History

International Assets Investment Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.01K Buy
+1,000
New +$4.44K ﹤0.01% 1967

Other funds holding FHTX

DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $902M AUM 21.74% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

International Assets Investment Management's FHTX Position: Q2 2026 in Review

International Assets Investment Management opened a new position in Foghorn Therapeutics (FHTX) in Q2 2026: 1,000 shares worth $5.01K. The stake represents ﹤0.01% of the portfolio and ranks #1967 among its holdings.

12 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • International Assets Investment Management held 1,000 shares of Foghorn Therapeutics worth $5.01K as of Q2 2026.
  • Foghorn Therapeutics was a new International Assets Investment Management position in Q2 2026.
  • Foghorn Therapeutics made up ﹤0.01% of International Assets Investment Management's portfolio in Q2 2026, its #1967 holding.
  • 12 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on International Assets Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.